The new induction of CTLA4 in GBM.pembro likely suppresses T cell activity, implying that the potential use of anti-CTLA-4 antibody blockade may enhance the co-stimulatory signaling through CD80/86’s engagement of T cells’ CD2844 in GBM.pembro patients. This evidence concerns the gene CTLA4 and glioblastoma.